Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data
- 587 Downloads
We executed a comparative systematic review and meta-analysis of the efficacy and toxicity of doublet BRAF/MEK inhibition versus single-agent BRAF inhibitor in the management of BRAF-mutant advanced melanoma.
Eligible studies included prospective studies evaluating doublet regimens versus BRAF-inhibitor monotherapy for the management of BRAF-mutant advanced melanoma.
Our search strategy yielded 200 potentially relevant citations from searched databases. After preclusion of ineligible studies, four studies were included in the final analysis. Efficacy analyses demonstrate that BRAF/MEK inhibition strategy is associated with a significant improvement in ORR [OR 1.35; 95 % CI (1.16, 1.58); P = 0.0002], PFS [HR 0.56; 95 % CI (0.49, 0.64); P < 0.00001] and OS [HR 0.70; 95 % CI (0.58, 0.84); P = 0.0001]. Moreover, this combination is associated with a higher RR for diarrhea [1.30; 95 % CI (1.30, 1.49); P = 0.0002], decreased ejection fraction [4.63; 95 % CI (2.56, 8.37); P = <0.00001], acneiform dermatitis [1.61; 95 % CI (1.03, 2.53); P = 0.04] and pyrexia [1.98; 95 % CI (1.72, 2.27); P < 0.00001].
Our meta-analysis has demonstrated that combination of MEK/BRAF inhibitors is associated with higher ORR, PFS and OS. However, this comes at the expense of a higher risk of selected toxicities.
KeywordsMelanoma Trametinib Dabrafenib Vemurafenib
Compliance with ethical standards
This study has not funded by any organizational body.
Conflict of interest
All authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 3.Michielin O, Höller C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev. 2015.Google Scholar
- 13.Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014.Google Scholar
- 20.McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Abdel-Rahman O, ElHalawani H, Ahmed H, Ellithy M. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2015 (ahead-of-print):1–13.Google Scholar
- 23.Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015 (ahead-of-print):1–13.Google Scholar
- 24.Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol. 2015 (ahead-of-print):1–13.Google Scholar
- 25.Gutzmer R, Hassel J, Kähler K, Loquai C, Mössner R, Ugurel S, et al. Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors. Der Hautarzt Z Dermatol Venerol Verwandte Geb. 2014;65(7):582–9.Google Scholar
- 26.Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015.Google Scholar
- 27.Yaeger R, Cercek A, O’Reilly E, Reidy E, editors. Pilot study ofvemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. American Society of Clinical Oncology, 50th annual meeting, Chicago.Google Scholar
- 28.Planchard D, Groen H., Kim T, Rigas J, Souquet P, Baik C et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. [2015 ASCO annual meeting (29 May–2 June 2015)]. 2015;33(15_suppl, May 20 supplement):8006.Google Scholar
- 29.Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015.Google Scholar
- 30.Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma a pooled analysis of 4 clinical trials. JAMA Oncol. 2015.Google Scholar